Development of rifapentine: the way ahead.
Mitchison
D A
DA
Department of Medical Microbiology, St. George's Hospital Medical School, London, UK. dmitchis@sghms.ac.uk
D000995:Antitubercular Agents / Q000008:administration & dosage*; D001682:Biological Availability; D002681:China; D002986:Clinical Trials as Topic; D004345:Drug Industry; D006723:Hong Kong; D006801:Humans; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D012293:Rifampin; C018421:rifapentine